Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome

Nathalie Roch From the Departments of Infectious Diseases, University Hospital, Grenoble, FranceCorrespondence[email protected]

Dimitri Salameire Departments of Pathology, University Hospital, Grenoble, France

Remy Gressin Departments of Clinical Haematology, University Hospital, Grenoble, France

Patrice Morand Departments of Virology, University Hospital, Grenoble, France

Olivier Epaulard From the Departments of Infectious Diseases, University Hospital, Grenoble, France

Patricia Pavese From the Departments of Infectious Diseases, University Hospital, Grenoble, France

Jean-Paul Brion From the Departments of Infectious Diseases, University Hospital, Grenoble, France

Jean-Paul Stahl From the Departments of Infectious Diseases, University Hospital, Grenoble, France

show all

Abstract

Alemtuzumab is an antibody binding to CD52, an antigen expressed on lymphocytes. This immunotherapy has been tested as potential therapy in haematological malignancies. We report adenoviral and enteroviral infections and an EBV positive B-cell lymphoma after alemtuzumab therapy. These fatal opportunistic complications have been rarely, if ever, reported before.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome

Information for

Open access

Opportunities

Help and information

Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature